Zalcitabine
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | HIVID | — | 1994-08-05 – 1996-06-26 | fda.gov ↗ |
| Approved | US (FDA) | HIVID | — | 1992-06-19 | fda.gov ↗ |
Trials 34
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 42 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zalcitabine | “It may include one or two nucleoside reverse transcriptase inhibitors, such as zidovudine, didanosine, lamuvidine, zalcitabine, stavudine), a non- nucleoside reverse...” NCT00032669 ↗40“tenofovir disoproxil fumarate (TDF), zalcitabine (ddC)” NCT00039741 ↗ |
| Known as | 2',3'-dideoxycytidine | “the drug 2',3'-dideoxycytidine ( zalcitabine; ddC ) in treating patients with AIDS or advanced AIDS related complex ( ARC ).” NCT00000704 ↗1“regimens of zidovudine ( AZT ) and 2',3'-dideoxycytidine ( zalcitabine; ddC )” NCT00000719 ↗ |
| Known as | ddC | “To determine if alternating zidovudine (AZT) and zalcitabine (dideoxycytidine; ddC) (first one and then the other) or intermittent therapy (1 week of drug then 1 week off) will...” NCT00000718 ↗28“To compare the effectiveness of zalcitabine ( dideoxycytidine; ddC ) therapy to zidovudine ( AZT ) in the treatment of AIDS or advanced AIDS related complex ( ARC ) in patients...” NCT00000678 ↗ “Primary: To compare the efficacy of zidovudine ( AZT ) given alone versus AZT plus didanosine ( ddI ) versus AZT plus zalcitabine ( dideoxycytidine; ddC ) in delaying the...” NCT00001022 ↗ “To determine the safety and efficacy of two doses of interferon alfa-2a ( IFN alfa-2a ) in combination with zidovudine ( AZT )/zalcitabine ( ddC ) versus AZT/ddC only in...” NCT00000754 ↗ “To show that zalcitabine (dideoxycytidine; ddC) is at least as effective as zidovudine (AZT) in the treatment of AIDS or advanced AIDS related complex (ARC), and also that ddC...” NCT00000679 ↗ “zidovudine ( AZT ) versus didanosine ( ddI ), AZT plus ddI, and AZT plus zalcitabine ( ddC ) in preventing disease progression in HIV-infected patients with CD4 counts of...” NCT00000625 ↗ “To evaluate the safety and efficacy of low and high doses of lamivudine ( 3TC ) in combination with zidovudine ( AZT ) and zalcitabine ( dideoxycytidine; ddC ) in combination with AZT.” NCT00002436 ↗ “interactive effects of didanosine ( ddI ) or zalcitabine ( dideoxycytidine; ddC ) with zidovudine ( AZT ) on the pharmacokinetics of U-87201E” NCT00000753 ↗ “Specifically, to evaluate zidovudine/zalcitabine ( AZT / ddC ) alone or in combination with either nevirapine or saquinavir ( Ro 31-8959 ).” NCT00002347 ↗ “safety, tolerability, and activity of zidovudine (AZT) and zalcitabine (dideoxycytidine; ddC) and the bloodstream levels of these drugs” NCT00000978 ↗ “To evaluate the safety of zalcitabine (dideoxycytidine; ddC) alone and in combination with zidovudine (AZT) versus AZT alone” NCT00000651 ↗ |
| Known as | Ddc (ddc) | ChEMBL registry synonym — accepted as the source's own label CHEMBL853 ↗ |
| Known as | dideoxycytidine | “To determine if alternating zidovudine (AZT) and zalcitabine (dideoxycytidine; ddC) (first one and then the other) or intermittent therapy (1 week of drug then 1 week off) will...” NCT00000718 ↗19“To compare the effectiveness of zalcitabine ( dideoxycytidine; ddC ) therapy to zidovudine ( AZT ) in the treatment of AIDS or advanced AIDS related complex ( ARC ) in patients...” NCT00000678 ↗ “Primary: To compare the efficacy of zidovudine ( AZT ) given alone versus AZT plus didanosine ( ddI ) versus AZT plus zalcitabine ( dideoxycytidine; ddC ) in delaying the...” NCT00001022 ↗ “To show that zalcitabine (dideoxycytidine; ddC) is at least as effective as zidovudine (AZT) in the treatment of AIDS or advanced AIDS related complex (ARC), and also that ddC...” NCT00000679 ↗ “To evaluate the safety and efficacy of low and high doses of lamivudine ( 3TC ) in combination with zidovudine ( AZT ) and zalcitabine ( dideoxycytidine; ddC ) in combination with AZT.” NCT00002436 ↗ “interactive effects of didanosine ( ddI ) or zalcitabine ( dideoxycytidine; ddC ) with zidovudine ( AZT ) on the pharmacokinetics of U-87201E” NCT00000753 ↗ “To evaluate the safety of zalcitabine (dideoxycytidine; ddC) alone and in combination with zidovudine (AZT) versus AZT alone” NCT00000651 ↗ “safety, tolerance, and pharmacokinetics of zidovudine (AZT) and zalcitabine (dideoxycytidine; ddC) when given in combination” NCT00001032 ↗ “To provide zalcitabine ( dideoxycytidine; ddC ) for use with zidovudine ( AZT ) in patients with advanced HIV infection.” NCT00002081 ↗ “To provide zalcitabine (dideoxycytidine; ddC) for patients with AIDS or advanced AIDS-related complex (ARC)” NCT00002279 ↗ “zalcitabine (dideoxycytidine; ddC) monotherapy is safe and tolerable” NCT00002265 ↗ |
| Known as | HIVID | “HIVID (Dideoxycytidine; Zalcitabine, ddC) Alone” NCT00002333 ↗ |
| Known as | NSC-606170 | ChEMBL registry synonym — accepted as the source's own label CHEMBL853 ↗ |
| Known as | RO 24-2027/000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL853 ↗ |
| Known as | Zalcitabina | ChEMBL registry synonym — accepted as the source's own label CHEMBL853 ↗ |
| Known as | Zalcitabine (dideoxycytidine,ddc) | ChEMBL registry synonym — accepted as the source's own label CHEMBL853 ↗ |
| Action | Inhibit | “AZT and ddC inhibit HIV by acting as reverse transcriptase chain terminators.” NCT00000754 ↗ |
| Modality | Small molecule | “nucleoside analog” NCT00000781 ↗ |
| Route | Oral | “taken orally every 8 hours” NCT00000653 ↗ |